Neurocrine Biosciences, Inc. Common Stock logo

Neurocrine Biosciences, Inc. Common Stock (NBIX) Technical Analysis

$138.40▲-0.39%

Market is closed - opens 7 PM, 28 Sep 2026

Insights

  • Neurocrine Biosciences Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
  • Based on analysis of the Oscillators technical indicator, the current market trend for Neurocrine Biosciences Inc. stock suggests that it is range bound and no decision can be made based on this information
  • Based on analysis of the Moving Averages technical indicator, Neurocrine Biosciences Inc. stock is in a downtrend↘️
  • Based on analysis of the Pivot Points, the current market trend for Neurocrine Biosciences Inc. stock suggests that it is a good time to sell or bad time to initiate a fresh position

Analysis Summary

Oscillators

Sell

Neutral

Buy

Moving Averages

Sell

Neutral

Buy

Pivots

Sell

Neutral

Buy

Oscillators

Name

Value

Action

Relative Strength Index
25.61
Buy
Stochastic
6.1, 5.13
Buy
Ultimate Oscillator
35.71
Neutral
Stochastic Relative Strength Index
0.0, 0.0
Neutral
Moving Average Convergence Divergence
-5.09, -3.77
Neutral

Moving Averages

Simple Moving Average

Period (Days)

Value

Action

10
145.78
Sell
20
150.88
Sell
50
158.96
Sell

Exponential Moving Average

Period (Days)

Value

Action

10
144.55
Sell
20
148.89
Sell
50
154.84
Buy

Volume Weighted Moving Average

Period (Days)

Value

Action

10
146.02
Sell
20
150.05
Sell
50
159.69
Sell

Double Exponential Moving Average

Period (Days)

Value

Action

10
139.29
Sell
20
142.45
Sell
50
150.85
Sell

Triple Exponential Moving Average

Period (Days)

Value

Action

10
137.42
Sell
20
140.21
Sell
50
143.57
Sell

Pivot

Pivot

Value

Resistance L3
144.34
Resistance L2
142.49
Resistance L1
140.71
Pivot Point
138.86
Support L1
137.08
Support L2
135.23
Support L3
133.45

*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.